x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Mendelspod Podcast

Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who"s who in genomics and genomic medicine. www.mendelspod.com

science & medicine natural sciences

All Episodes

33:04

Nevermind the $200 Genome, Element CEO Molly He Says...

Mendelspod Podcast ·

2023/03/23

"We’re not a sequencing company," says Molly He, CEO and co-founder of Element Biosciences in our first interview with the leader of the hot new sequencing company which seemed to come out of nowhere this past year. “We’re a biology company.”Not a sequencing company? Element has just taken the lead in the race toward cheap clinical genomes, and their CEO is putting that news aside in today’s interview. Instead, she’s much more interested in touting the company’s core technology “avidity.” The term

en

26:52

3D Genomics Solves Cancer Case Where Sequencing Came...

Mendelspod Podcast ·

2023/03/16

Biology is complex, and the life science tool kit continues to expand to meet the challenge of that complexity taking us into the world of multi omics and beyond. Today we talk about 3D genomics and what this additional three-dimensional structural information is telling not just researchers, but clinicians, particularly in oncology. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

23:33

New Spatial Company Maps Cell Surface Proteome...

Mendelspod Podcast ·

2023/03/08

Today we talk with Simon Fredriksson, CEO and co-founder of Pixelgen Technologies, a company just out of stealth offering spatial technology that maps cellular surface proteins at the single cell level. Called molecular pixelation, the breakthrough technology is designed to first target immune cells. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

45:07

John Greally on His Latest Review of Epigenomics

Mendelspod Podcast ·

2023/02/23

Editor's Note: Theral's mic malfunctioned in this interview. Fortunately the not as good backup mic did work and John has a good mic. Our apologies.John Greally joins us today. He is the founding Director of the Albert Einstein College of Medicine’s Center for Epigenomics. He’s a pediatrician and a clinical geneticist with appointments in both at Einstein. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit

en

26:16

President of ASHG on Eugenics Apology, Diversity...

Mendelspod Podcast ·

2023/02/15

Last month the American Society of Human Genetics (ASHG) took a quite remarkable step, putting out a formal statement of apology for its past history of involvement with eugenics. Some say it’s long overdue while some of us didn’t know about this history. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

39:52

23andMe Launches New Personalized Healthcare...

Mendelspod Podcast ·

2023/02/02

23andMe occupies its own place in the world of genomics. Known for its vision to democratize human genomic information, the company has always gone big and bold, and sometimes controversial. Today we don’t hear much controversy—is that because their approach has won out? In any case, they have certainly achieved a scale that surpasses any other genetic testing company. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit

en

31:27

Converting Digital to Biological: John Gill, Telesis Bio

Mendelspod Podcast ·

2023/01/23

Remember all those firsts for synthetic biology that we heard about coming from Craig Venter’s company, Synthetic Genomics in San Diego? The first genome of a whole organism transplanted. First genome synthesized. First synthetic life created. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

33:38

50% Not Tested: Precision Oncology with Jerome...

Mendelspod Podcast ·

2023/01/17

Oncology has emerged as the most successful disease area for precision medicine. Last year, as the genetic testing industry went through a royal shake-up brought on mostly by external market forces, it's been no surprise that precision oncology has been touted as a core strength. As the industry now works "to be more lean and profitable"--new language one hears these days, cancer testing will be a big part of that effort. This is a public episode. If you'd like to discuss this with other

en

37:35

Paul Freemont on Synthetic Biology in the UK

Mendelspod Podcast ·

2023/01/05

To begin the year, we head across the pond for an outlook on the thriving community of synthetic biology in the United Kingdom.Paul Freemont was a co-author of the UK's synthetic biology roadmap and co-directs SynbiCITE, the national center for the commercialization of synthetic biology. A few years ago the government put an initial investment of $300 million pounds into the field, and "everything was going swimmingly well," says Paul. "Then COVID happened." This is a public episode. If you'd

en

40:32

The Bioengineered Hangover Cure: Changing the...

Mendelspod Podcast ·

2022/12/22

Our goal with today’s show was twofold: bring you a practical holiday gift idea and to take you into the world of a synthetic biology entrepreneur. Our guest: Zack Abbott, CEO of ZBiotics.Zack is a scientist turned businessman who is on a mission to change the conversation around GMOs. His first product is a genetically engineered probiotic that alleviates the morning-after hangover by breaking down acetaldehyde. Zack says he chose this product because it’s something consumers can choose to

en

39:22

Lance Baldo of Freenome on their Approach to Early...

Mendelspod Podcast ·

2022/12/08

When excitement around early cancer detection first surfaced, we heard about the “pan-cancer” test that would look for any and all cancers, and early. Now that we’re some years into it, the approach is turning out to be more of a narrow one. Which cancer will we likely see targeted first with an FDA cleared test? Colorectal, according to today’s guest. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit

en

34:30

Mara Aspinall on COVID

Mendelspod Podcast ·

2022/11/29

Winter is here. In America, we're just back from the Thanksgiving holiday when many of us travel and get together. And so far there is no great COVID surge this year. Or is there?Today's guest says there likely is, and we don't know it because of the most significant shift in our pandemic response: at-home testing. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

44:25

Terry Lo of Vizgen on Spatial Genomics

Mendelspod Podcast ·

2022/11/27

Today spatial biology company, Vizgen, makes their debut on on the program.When Vizgen CEO Terry Lo was first involved in developing what we now call spatial biology at Perkin Elmer, he admits that he never thought it would have a genomics side to it. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

52:31

Proteomics at Scale Empowers Genomics in New Ways:...

Mendelspod Podcast ·

2022/11/22

It’s the age of multi omics. Or multi comics, if you don't catch spell check. A few weeks ago at the annual meeting of the American Society for Human Genetics, we were pleased to find not only genomics companies but some proteomics outfits finding a home. As we chatted with one of these, Olink Proteomics, we were blown away to hear that they were announcing the publication of 1,000 scientific papers. It wasn’t so long ago that genomics companies were boasting this kind of milestone. Has

en

35:46

A New Tool in the Genomics Kit with Ivan Liachko of...

Mendelspod Podcast ·

2022/11/14

Have you ever heard of proximity ligation? We knew of it in research form back in the day, but not that it had been commercialized until this summer. It’s not every day we come across a powerful new genomics tool on this program. Which begs the question, where have Ivan Liachko and his company, Phase Genomics, been hiding?The company received a grant this summer from the Bill Gates Foundation as well as the NIH to pursue phage therapeutics. That’s using viruses to go after bacterial

en

34:42

Paul Kruszka of GeneDx/Sema4 on Groundbreaking...

Mendelspod Podcast ·

2022/11/13

Last week, during the first International Conference on Newborn Sequencing, a landmark study to sequence the genomes of 100,000 newborns was announced. Called the GUARDIAN study, the project is the brainchild of Wendy Chung, Professor of Pediatrics at Columbia University. The study will take place in New York State and is somewhat similar to an ongoing project in the U.K. being done by Genomics England. This is a public episode. If you'd like to discuss this with other subscribers or get access to

en

33:43

Is PGx Having a Moment? Kristine Ashcraft, Invitae

Mendelspod Podcast ·

2022/11/10

Pharmacogenomic testing, or PGx, is considered low-hanging fruit, a no-brainer for the application of genetic testing in the clinic. And some may think it is small fruit. Not so, says today’s guest, Kristine Ashcraft."Currently we lose a life every two minutes in the United States to non-optimized medications,” says Kristine in today’s show. She has spent over twenty years working to see pharmacogenomic testing adopted into standard-of-care medicine. Kristine serves today as the Medical Affairs

en

36:41

Christian Henry on Revio, Onso and the New Vision at...

Mendelspod Podcast ·

2022/11/03

Last week with a crowd of 1,200 customers in a Los Angeles nightclub, sequencing company Pacific Bioscience launched two new sequencers, both long and short read, Revio and Onso. It was a night of great technology, music, and anticipation. Their customers have waited a long time for this moment. Revio offers long read whole genomes at scale for under $1,000. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit

en

41:46

The Revolution in Single Molecule Sequencing...

Mendelspod Podcast ·

2022/10/18

A new generation of biologists is pushing the limits of third-generation sequencing, furthering the technology's development and defining new applications to answer biology’s most pressing questions.This is the express goal for the lab of Vijay Ramani, assistant professor at UCSF in the department of Biophysics and Biochemistry. Vijay also has an appointment in the Institute of Data Science and Biotechnology at the Gladstone Institute, and in 2019 he was named to the Forbes 30 under 30 rising stars

en

47:28

Will Hwang of Mass General on Discovery of Novel...

Mendelspod Podcast ·

2022/10/11

In our age of specialization, today’s guest, Dr. Will Hwang of Massachusetts General, went against the trend and received three bachelor degrees in different fields.Or is this the new trend?Will says that despite the diversity of pursuits, there was a thread that ran throughout his life as a student. He always liked to look at things at the fundamental unit. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit

en

532 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事